Contact

[email protected]
+1 941 755 6644

Follow

Info

Welcome to the Archer Pharmaceuticals website! Use this panel to navigate all the pages of the site.

About Archer Pharamaceuticals
Archer Pharmaceuticals, Inc. (Archer) was founded in 2008 and specializes in targeted drug discovery for Alzheimer’s disease.

Our Founding

Led by Chief Executive Officer and Chief Scientific Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer and Associate Chief Scientific Officer Fiona Crawford, Ph.D., Archer was created based on the groundbreaking research conducted at the Roskamp Institute in Sarasota, Florida.

Included in this research is clinical development of Nilvadipine as a therapeutic for Alzheimer’s Disease. A Phase I/IIA human clinical trial was conducted in Alzheimer’s patients in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland. This trial showed that Nilvadipine was well-tolerated in Alzheimer’s disease patients, and, together with extensive preclinical data in laboratory models of Alzheimer’s Disease, laid the foundation for a Phase III double-blind, placebo-controlled clinical trial of Nilvadipine (the NILVAD study) which was concluded in 2017. Analyses are ongoing and study results will most likely become public in Q4 2017 - Q1 2018.

https://www.archerpharmaceuticals.com/Our%20Mission
Our Mission
Archer and its world-class team of researchers and scientists are committed to identifying quality therapeutics as new treatments and preventions for Alzheimer’s disease.
https://www.archerpharmaceuticals.com/Our%20Strategy
Our Strategy
The Archer strategy is two-fold:To take existing drugs with known safety profiles into the clinic for the new indication of Alzheimer’s disease and related dementias; and to use these drugs as templates for the development of new, even more effective drugs.
https://www.archerpharmaceuticals.com/Our%20Motivation
Our Motivation
By 2025, the number of people age 65 and older in the US with Alzheimer's disease is estimated to reach 7.1 million—a 40 percent increase from the 5 million age 65 and older currently affected. By 2050, the US population effected by Alzheimer's disease may nearly triple, from 5 million to a projected 13.8 million (over 46 million worldwide), barring the development of medical breakthroughs to prevent, slow or stop the disease.